Cord blood-derived CD133+ cells improve cardiac function after myocardial infarction

Researchers at the Pontifícia Universidade Católica do Paraná and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence. HUCB-derived EPCs could be an alternative to rescue impaired stem cell function in the sick and elderly.

Read the whole article on Physorg

More from Physorg